AERI

AERI

Last Updated:

Q3 '20

Aerie Pharmaceuticals

We are committed to building a major ophthalmic pharmaceutical company. Our pathway to global leadership in eye care is based on continuous scientific innovation, world-class clinical development, and company-wide operational excellence in the pursuit of novel treatments for diseases of the eye with significant unmet need.

Cash

$218M

Burn Rate (Qtr)

$21.5M

Pipeline Information

Click drug data to see upcoming trial info and prior data

Drug | Disease

Stage | Exp Date

Prior Data

Rocklatan (Roclanda - EU) (netarsudil (ROCK - rho kinase inhib) & latanoprost (ophthalmic solution)

ophthalmology

Quarterly Sales (Approved)

Feb 2021 (est)

Rhopressa (Rhokiinsa - EU) (netarsudil)(ROCK - rho kinase inhibitor)

ophthalmology

Quarterly Sales (Approved)

Feb 20 (Est)

AR-1105

Diabetic macular edema (DME) and Retinal vein occlusion (RVO)

Phase 3 initiation

TBD

AR-15512 (TRPM8 agonist eye drop)

Dry Eye Disease (DED)

Phase 2b (COMET-1) readout

Q3 2021

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon